Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02057770 |
Recruitment Status
:
Recruiting
First Posted
: February 7, 2014
Last Update Posted
: March 1, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this research study is to look at overall health status and how acute myeloid leukemia (AML) responds to a stem cell transplant when followed with cyclophosphamide. Some participants enrolling in this study may receive a transplant from a sibling, some may receive a transplant from a matched unrelated donor, and some may receive what is called a haploidentical transplant. A haploidentical stem cell transplant is a type of transplant that occurs when a person who needs a transplant cannot find a donor who exactly matches their tissue type (either among family members or through a matched unrelated donor). When no matched donor is available, half-matched related (haploidentical) donors may be used. Haploidentical donors are first degree relatives such as siblings, children, or parents.
People who undergo a stem cell transplant can experience complications such as rejection of the stem cell transplant or severe graft-versus-host disease (GVHD). GVHD occurs when some of the cells from the donor attack the recipient's tissues, resulting in mild, moderate, or even life-threatening side effects to the recipient's skin, stomach, intestines, and liver. However, recent research has shown that receiving cyclophosphamide after stem cell transplant can improve the outcomes of the transplant, and that is the purpose of this study.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Leukemia, Myeloid, Acute | Drug: busulfan Drug: fludarabine phosphate Radiation: total-body irradiation (TBI) Procedure: Stem cell transplant Drug: cyclophosphamide Drug: tocilizumab | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 33 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML |
Actual Study Start Date : | February 28, 2014 |
Estimated Primary Completion Date : | August 31, 2018 |
Estimated Study Completion Date : | November 30, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (preparative regimen, transplant, cyclophosphamide)
BUSULFAN AND FLUDARABINE BASED PREPARATIVE REGIMEN: Patients receive busulfan IV over 3 hours on days -7 to -4, fludarabine phosphate IV over 30-60 minutes on days -6 to -2, and cyclophosphamide IV over 60 minutes on days -3 and -2. OR FLUDARABINE AND TBI BASED PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -4 and undergo TBI twice daily on days -3 to 0. AND DONOR CELL INFUSION: Patients undergo HLA-matched sibling stem cell transplant, HLA-matched unrelated, or HLA-haploidentical transplant on day 0. AND POST-TRANSPLANT CYCLOPHOSPHAMIDE: Patients receive cyclophosphamide IV over 90 minutes on days 3 and 4. |
Drug: busulfan
Other Name: Myleran®
Drug: fludarabine phosphate
Other Names:
Radiation: total-body irradiation (TBI)
Procedure: Stem cell transplant
Drug: cyclophosphamide
Other Names:
|
Experimental: CRS preventive regimen
The final ~15 people enrolled who will be recipients of haploidentical transplants will receive tocilizumab IV over 60 minutes 6-12 hours prior to the start of the donor cell infusion.
|
Drug: tocilizumab
Other Names:
|
- Event Free Survival (EFS) rate [ Time Frame: Assessed at 100 days post-transplant ]The time from date of first dose of the preparative regimen until failure to engraft, treatment failure, disease progression/relapse, or death from any cause (whichever occurs first). Rates will be calculated with exact 95% confidence intervals.
- Overall Survival (OS) [ Time Frame: Assessed at 1 year post-transplant ]The time from the date of day 0 until death from any cause. Rates will be calculated with exact 95% confidence intervals.
- Rate of Leukemia Free Survival (LFS) [ Time Frame: Assessed at 100 days post-transplant ]The time from date of day 0 until disease progression or death from any cause (whichever occurs first). Rates will be calculated with exact 95% confidence intervals. For patients who achieve CR, CRc, or CRi only.
- Transplant Related Mortality (TRM) Rate [ Time Frame: Assessed at 100 days post-transplant ]Death from causes other than disease relapse or progression prior to Day +100 visit. Rates will be calculated with exact 95% confidence intervals.
- Time to neutrophil engraftment [ Time Frame: Assessed up to day 30 ]Defined as an untransfused platelet measurement > 20,000/ x10^9/L x 3 consecutive days. Kaplan-Meier models will be used to estimate median time to platelet engraftment and plot a time to event curve. Cox proportional hazards models may be used to explore the effect of covariates on time to platelet engraftment.
- Incidence of acute GVHD [ Time Frame: Up to 100 days post-transplant ]The incidence and severity of acute GVHD will be determined. Rates will be calculated with exact 95% confidence intervals.
- Incidence of chronic GVHD [ Time Frame: 1 year post-transplant starting at day +100 ]The incidence and severity of chronic GVHD will be determined. Rates will be calculated with exact 95% confidence intervals.
- Time to platelet engraftment [ Time Frame: Assessed up to day 100 ]Defined as an untransfused platelet measurement > 20,000/ x10^9/L x 3 consecutive days. Kaplan-Meier models will be used to estimate median time to platelet engraftment and plot a time to event curve. Cox proportional hazards models may be used to explore the effect of covariates on time to platelet engraftment.
- Rate of CRS with and without tocilizumab prophylaxis [ Time Frame: Assessed up to day 7 ]To investigate the rate of cytokine release syndrome with and without tocilizumab prophylaxis in patients with active AML who undergo haploidentical transplantation

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- AML without complete remission (CR/CRc/CRi) after at least 2 induction therapies OR
- AML that has relapsed within 6 months after obtaining a CR OR
- AML that has relapsed more than 6 months after obtaining a CR, and has treatment failure (TF) or progressive disease (PD) following at least 1 re-induction regimen OR
- AML that has relapsed post Allogeneic transplantation
- Active AML (bone marrow blasts ≥ 5% by morphology, staining, or flow) and/or presence of estramedullary disease
-
Available HLA-haploidentical donor that meets the following criteria:
- Blood-related family member (sibling (full or half), offspring, or parent, cousin, niece or nephew, aunt or uncle, or grandparent)
- At least 18 years of age
- HLA-haploidentical donor/recipient match by at least low-resolution typing per institutional standards
- In the investigator's opinion, is in general good health, and medically able to tolerate leukapheresis required for harvesting HSC
- No active hepatitis
- Negative for HTLV and HIV
- Not pregnant
NOTE: there were HLA-matched sibling and HLA-matched unrelated donor cohorts, but those closed without completion of accrual with Amendment 11
- Karnofsky performance status ≥ 50 %
-
Adequate organ function as defined below:
- Total bilirubin ≤ 2.5 mg/dl (unless the patient has a history of Gilbert's syndrome)
- AST(SGOT) and ALT(SGPT) ≤ 3.0 x IULN
- Creatinine ≤ 2.0 x IULN OR estimated creatinine clearance ≥ 30 mL/min/1.73 m2 by Cockcroft-Gault Formula
- Oxygen saturation ≥ 90% on room air
- LVEF ≥ 40%
- FEV1 and FVC ≥ 40% predicted, DLCOc ≥ 40% predicted. If DLCO is < 40%, patients will still be considered eligible if deemed safe after a pulmonary evaluation.
- At least 18 years of age at the time of study registration
- Able to understand and willing to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable)
Exclusion Criteria:
- Circulating blast count ≥ 10,000/uL by morphology or flow cytometry (cytoreductive therapies including leukapheresis or hydroxyurea are allowed)
- Known HIV or Active hepatitis B or C infection
- Known hypersensitivity to one or more of the study agents
- Currently receiving or has received any investigational drugs within the 14 days prior to the first dose of study drug (Day -7)
- Currently receiving or has received any intensive chemotherapy within the 14 days prior to the first dose of study drug (Day -7) (hydrea or other non-intensive regimens such as decitabine may be used but must stop at least one day prior to the first dose of study drug)
- Pregnant and/or breastfeeding
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmias, or psychiatric illness/social situations that would limit compliance with study requirements.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02057770
Contact: Todd Fehniger, M.D., Ph.D. | 314-747-8439 | tfehnige@wustl.edu |
United States, Missouri | |
Washington University School of Medicine | Recruiting |
Saint Louis, Missouri, United States, 63110 | |
Contact: Todd Fehniger, M.D., Ph.D. 314-747-8439 tfehnige@wustl.edu | |
Principal Investigator: Todd Fehniger, M.D., Ph.D. | |
Sub-Investigator: John DiPersio, M.D., Ph.D. | |
Sub-Investigator: Peter Westervelt, M.D., Ph.D. | |
Sub-Investigator: Jesse Keller, M.D. | |
Sub-Investigator: Camille Abboud, M.D., Ph.D. | |
Sub-Investigator: Amanda Cashen, M.D. | |
Sub-Investigator: Meagan Jacoby, M.D., Ph.D. | |
Sub-Investigator: Iskra Pusic, M.D. | |
Sub-Investigator: Mark Schroeder, M.D. | |
Sub-Investigator: Keith Stockerl-Goldstein, M.D. | |
Sub-Investigator: Geoffrey Uy, M.D. | |
Sub-Investigator: Ravi Vij, M.D. | |
Sub-Investigator: Kristan Augustin, PharmD | |
Sub-Investigator: Rizwan Romee, M.D. |
Principal Investigator: | Todd Fehniger, M.D., Ph.D. | Washington University School of Medicine |
Additional Information:
Responsible Party: | Washington University School of Medicine |
ClinicalTrials.gov Identifier: | NCT02057770 History of Changes |
Other Study ID Numbers: |
201401080 |
First Posted: | February 7, 2014 Key Record Dates |
Last Update Posted: | March 1, 2018 |
Last Verified: | February 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes | |
Studies a U.S. FDA-regulated Device Product: | Yes | |
Device Product Not Approved or Cleared by U.S. FDA: | No | |
Pediatric Postmarket Surveillance of a Device Product: | No | |
Product Manufactured in and Exported from the U.S.: | No |
Additional relevant MeSH terms:
Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms by Histologic Type Neoplasms Cyclophosphamide Fludarabine phosphate Busulfan Fludarabine Vidarabine Immunosuppressive Agents Immunologic Factors |
Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antimetabolites, Antineoplastic Antimetabolites Antiviral Agents Anti-Infective Agents |